Summary
Synopsis
Dopexamine hydrochloride is a novel synthetic catecholamine, structurally related to dopamine, with marked intrinsic agonist activity at β2- adrenoceptors, lesser agonist activity at dopamine DA1-and DA2- receptors and β1- adrenoceptors, and an inhibitory action on the neuronal catecholamine uptake mechanism. The drug is administered by intravenous infusion, and is characterised by a rapid onset and short duration of action. Short term haemodynamic studies in volunteers and patients with severe chronic heart failure have indicated that dopexamine hydrochloride reduces afterload through pronounced arterial vasodilatation, increases renal perfusion by selective renal vasodilatation and evokes mild cardiac stimulation through direct and indirect positive inotropism. Preliminary smallscale noncomparative studies indicate that dopexamine hydrochloride displays beneficial haemodynamic effects in patients with acute heart failure and those requiring haemodynamic support following cardiac surgery, and that these effects are substantially maintained during longer term administration (≤24 hours). Dopexamine hydrochloride appears to be generally well tolerated. Nausea and vomiting are the most frequently reported adverse effects, and respond to dosage reduction. Occasional reports of chest pain/angina pectoris precipitated by tachycardia indicates the need for caution in the use of dopexamine hydrochloride in patients with ischaemic heart disease. Thus, dopexamine hydrochloride may prove to be a useful alternative to dopamine and dobutamine in the treatment of acute heart failure and the postoperative management of low cardiac output states, although controlled studies are required to establish its efficacy and tolerability with respect to that of established therapies.
Pharmacodynamic Studies
Dopexamine hydrochloride displays dopaminergic and β2-adrenergic agonist activity in isolated cardiac and vascular preparations, and produces a marked inhibition of neuronal catecholamine uptake. In dogs, dopexamine hydrochloride reduced blood pressure and afterload, increased heart rate and improved indices of myocardial contractility. The positive chronotropic and inotropic actions of the drug resulted from indirect β1-adrenoceptor stimulation, arising from baroreflex activation and inhibition of norepinephrine (noradrenaline) reuptake, and from direct cardiac β2-adrenoceptor stimulation. Dopexamine hydrochloride increased renal, myocardial and skeletal muscle blood flow. The drug displayed activity against ischaemic arrhythmias in the rat.
In healthy volunteers, short term (≤ 3 hours) intravenous infusion of dopexamine hydrochloride resulted in dose-related increases in cardiac output and heart rate, reductions in renal vascular resistance and minimal changes in blood pressure. In patients with chronic congestive heart failure, dopexamine hydrochloride augmented left ventricular performance, producing a pronounced systemic vasodilatation, positive chronotropy and mild positive inotropy, and minimal changes in cardiac filling pressures and arterial blood pressure. Dopexamine hydrochloride-mediated improvements in isovolumic phase indices of left ventricular contractility were indicative of a direct positive inotropism. Blood flow to the hepatic-splanchnic and renal vascular beds was selectively increased, and accompanied by marginal increases in natriuresis and diuresis. Myocardial oxygen consumption and metabolic function were unaltered by dopexamine hydrochloride, while myocardial efficiency was slightly improved. Plasma norepinephrine levels were either unaffected or increased. Longer term (≤ 72 hours) intravenous infusion of high dose dopexamine hydrochloride was frequently characterised by a rapid and progressive attenuation of the haemodynamic response in patients with chronic congestive heart failure. Direct drug comparisons, performed in patients with chronic congestive heart failure, indicated that the acute haemodynamic effects of dopexamine hydrochloride were similar to those of dobutamine, with both drugs reducing preload and increasing cardiac output through enhanced inotropy and reduced afterload. Dopexamine hydrochloride had a comparable effect to sodium nitroprusside on loading conditions in chronic congestive heart failure, but displayed a more marked inotropic effect coupled with a less pronounced tachycardic action. In patients with left ventricular dysfunction, dopexamine hydrochloride showed greater chronotropism and preload-reducing properties than dopamine.
Pharmacokinetic Studies
There is little published information on the pharmacokinetic properties of dopexamine hydrochloride in animals or humans. Dose titration of dopexamine hydrochloride 1 to 4 μg/kg/min resulted in proportional increases in plasma drug concentrations in volunteers, with a peak of 124 mg/L after 1 hour. On termination of infusion, plasma drug concentrations declined rapidly and monoexponentially with an elimination half-life of 7 minutes (vs 11 minutes in patients with low cardiac output) and a plasma clearance of 36 ml/min/kg (vs 17 ml/min/kg in patients following cardiac surgery). Tissue distribution of dopexamine hydrochloride was extensive, with the drug acting as a substrate for the extraneuronal catecholamine uptake mechanism (Uptake2). Dopexamine hydrochloride was extensively metabolised by O-methylation and subsequent sulphate conjugation to yield 2 major products which were excreted with the parent drug in the urine and faeces. Urinary excretion was biphasic with a terminal half-life of 4 days; the 2-methoxy, 1-sulphate metabolite accounted for more than 90% of the excreted drug recovered from the urine. Over 12 days after administration, the urinary and faecal routes accounted for the elimination of more than 50% and 20%, respectively, of the original dose.
Therapeutic Trials
Noncomparative dose-titration studies indicated that intravenous infusions of dopexamine hydrochloride 0.5 to 6.0 μg/kg/min produced a beneficial systemic and renal vasodilatation, in conjunction with enhanced diuresis and improvements in indices of myocardial function, in patients with acute heart failure. In contrast to its action in patients with chronic heart failure, dopexamine hydrochloride lacked significant preloadreducing properties in those with acute heart failure. Long term (24 hours) intravenous infusion of dopexamine hydrochloride in patients with acute heart failure following myocardial infarction was associated with sustained haemodynamic improvements, with no evidence of appreciable tolerance to the haemodynamic effects.
Noncomparative dose-titration studies in patients with compromised left ventricular function subsequent to cardiac surgery reported that intravenous infusions of dopexamine hydrochloride 1.0 to 10.0 μg/kg/min produced dose-related increases in cardiac output and heart rate, reductions in afterload, but no changes in preload. These haemodynamic effects were associated with a tendency towards increased diuresis.
Adverse Effects
Dopexamine hydrochloride was well tolerated during short and extended term (≤ 72 hours) intravenous infusion at doses of 0.5 to 10.0 μg/kg/min. Nausea, vomiting, tachycardia, chest pain/angina pectoris, ventricular ectopy and tremor (which occurred in 2% to 5% of patients) accounted for the majority of reported adverse effects and responded rapidly to dose reduction or infusion termination. However, chest pain/angina pectoris precipitated by tachycardia have been chiefly encountered in patients with pre-existing ischaemic heart disease. In most patients, the dopexamine hydrochloride-induced tachycardia is within limits of clinical acceptability and there is no evidence of significant arrhythmogenic potential. Reversible reductions in neutrophil and platelet counts have been recorded in healthy subjects receiving short term intravenous infusions of dopexamine hydrochloride 1 to 4 μg/kg/min. There have been no reports of biochemical abnormalities following administration of the drug to normoglycaemic patients.
Dosage and Administration
For the treatment of acute heart failure and haemodynamic support in patients following cardiac surgery, dopexamine hydrochloride should be infused intravenously at an initial dose of 0.5 μg/kg/min and then titrated upwards in dosage increments of 1.0 μg/ kg/min, in accordance with haemodynamic response, to a maximum of 6.0 μg/kg/min. The use of dopexamine hydrochloride is contraindicated in patients with thrombocytopenia. Caution is advised in the case of patients with hyperglycaemia and hypokalaemia in view of the drug’s β-adrenergic action.
Similar content being viewed by others
References
Bass AS. Renal effects of dopexamine hydrochloride. Abstract. Pharmacologist 31: 134, 1989
Bass AS, Kohli JD, Lubbers N, Goldberg LI. Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog. Journal of Pharmacology and Experimental Therapeutics 242: 940–944, 1987
Bass AS, Murphy MB, Kohli JD, Goldberg LI. Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug. Journal of Cardiovascular Pharmacology 13: 667–671, 1989
Baumann G, Felix SB, Filcek SAL. Usefulness of dopexamine hydrochloride versus dobutamine in chronic congestive heart failure and the effects on haemodynamics and urine output. In press, 1990
Baumann G, Gutting M, Pfafferott C, Ningel K, Klein G. Comparison of acute haemodynamic effects of dopexamine hydrochloride, dobutamine and sodium nitroprusside in chronic heart failure. European Heart Journal 9: 503–512, 1988
Bayliss J, Thomas L, Poole-Wilson P. Acute haemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, captopril and nitrate. Journal of Cardiovascular Pharmacology 9: 551–554, 1987
Biro GP, Douglas JR, Keon WJ, Taichman GC. Changes in regional blood flow distribution induced by infusions of dopexamine hydrochloride or dobutamine in anesthetized dogs. American Journal of Cardiology 62: 30C-36C, 1988
Bodenham AR, Park GR. Dopexamine hydrochloride, a novel drug with renal vasodilator properties: two case studies. Intensive Care Medicine 14: 663–665, 1988
Böhm M, Kemkes B, Pieske B, Schnabel P, Erdmann E. The β2-adrenoceptor-mediated positive inotropic effect of dopexamine in the failing human heart. British Journal of Pharmacology 95 (Suppl.): 491P, 1988
Bonnier JJR, Read BH. Dopexamine hydrochloride and dobutamine: a comparison of the haemodynamic effects in patients with chronic cardiac failure. TGO-Tijdschrift voor Therapie Geneesmiddel en Onderzoek — JDR Journal of Drug Therapy and Research 13: 237–240, 1988
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, et al. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circulation Research 59: 297–309, 1986
Brodde O-E, Zerkowski H-R, Borst HG, Maier W, Michel MC. Drug- and disease-induced changes of human cardiac β1- and β2-adrenoceptors. European Heart Journal 10 (Suppl. B): 38–44, 1989
Brown RA, Dixon J, Farmer JB, Hall JC, Humphries RG, et al. Dopexamine: a novel agonist at peripheral dopamine receptors and β2-adrenoceptors. British Journal of Pharmacology 85: 599–608, 1985a
Brown RA, Farmer FB, Hall JC, Humphries RG, O’Connor SE, et al. The effects of dopexamine on the cardiovascular system of the dog. British Journal of Pharmacology 85: 609–619, 1985b
Brown RA, Farmer JB, Hall JC, Kasprzak L, O’Connor SE, et al. FPL 60278 (dopexamine): actions at pre and postjunctional dopamine receptors and at α- and β-adrenoceptors. British Journal of Pharmacology 81 (Suppl.): 120P, 1984
Brown JE, McLeod AA, Ahand DG. In support of cardiac chronotropic beta 2 adrenoreceptors. American Journal of Cardiology 57: 11F-16F, 1986
Clarke AJ. Pre-clinical safety evaluation and drug disposition studies of DOPACARD® (dopexamine hydrochloride). Abstract. Presented at Symposium, Ancienne Faculté de Médecine, University de Paris, 12–13 September 1987
Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure. New England Journal of Medicine 297: 254–258, 1977
Colan SE, Borow KM, Neumann A. The left ventricular end-systolic wall stress — velocity of fiber shortening relation: a load independent index of myocardial contractility. Journal of the American College of Cardiology 4: 715–724, 1984
Colardyn FA, Vandenbogaerde JF. Use of dopexamine hydrochloride in intensive care patients with low-output left ventricular heart failure. American Journal of Cardiology 62: 68C-72C, 1988
Dawson JR, Thompson DS, Signy M, Juul SM, Turnbull P, et al. Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure. British Heart Journal 54: 313–320, 1985
De Marco T, Kwasman M, Lau D, Chatter K. Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost. American Journal of Cardiology 62: 57C-62C, 1988
Foulds RA. Clinical development of dopexamine hydrochloride (Dopacard) and an overview of its hemodynamic effects. American Journal of Cardiology 62: 41C-45C, 1988
Francis GS, Sharma B, Hodges M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. American Heart Journal 103: 995–1000, 1982
Goldberg LI, Bass AS. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride. American Journal of Cardiology 62: 37C-40C, 1988
Goldstein RE, Beijer GD, Stampfer M, Epstein SE. Impairment of autonomically mediated heart rate control in patients with cardiac dysfunction. Circulation Research 36: 571–578, 1975
Gollub SB, Emmot WW, Johnson DE, Sights KA, Wilson DB, et al. Hemodynamic effects of dopexamine hydrochloride infusions of 48 to 72 hours’ duration for severe congestive heart failure. American Journal of Cardiology 62: 83C-88C, 1988
Hakim M, Foulds R, Latimer RD, English TAH. Dopexamine hydrochloride a β2adrenergic and dopaminergic agonist; haemodynamic effects following cardiac surgery. European Heart Journal 9: 853–858, 1988
Hunter DN, Gray H, Mudaliar Y, Morgan C, Evans TW. The effects of dopexamine hydrochloride on cardiopulmonary haemodynamics following cardiopulmonary bypass surgery. International Journal of Cardiology 23: 365–371, 1989
Jackson NC, Taylor SH, Frais MA. Hemodynamic comparison of dopexamine hydrochloride and dopamine in ischemic left ventricular dysfunction. American Journal of Cardiology 62: 73C-77C, 1988
Jamison M, Widerhorn J, Weber L, Campese V, Vasquez J, et al. Central and renal hemodynamic effects of a new agonist at peripheral dopamine- and beta-2 adrenoceptors (dopexamine) in patients with heart failure. American Heart Journal 117: 607–614, 1989
Jaski BE, Peters C. Inotropic, vascular and neuroendocrine effects of dopexamine hydrochloride and comparison with dobutamine. American Journal of Cardiology 62: 63C-67C, 1988
Jaski BE, Wijns W, Foulds R, Serruys PW. The haemodynamic and myocardial effects of dopexamine: a new β2-adrenoceptor and dopaminergic agonist. British Journal of Clinical Pharmacology 21: 393–400, 1986
Katz RL, Lord CO, Eakins KE. Anaesthetic-dopamine cardiac arrhythmias and their prevention by beta adrenergic blockade. Journal of Pharmacology and Experimental Therapeutics 158: 40–45, 1967
Lang RM, Borow KM, Neumann A, Carroll JD, Weinert L, et al. Role of the β2adrenoeeptor in mediating positive inotropic activity in the failing heart and its relation to the hemodynamic actions of dopexamine hydrochloride. American Journal of Cardiology 62: 46C-52C, 1988
Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. American Journal of Cardiology 62: 86E-93E, 1988
Leier CV, Binkley PF, Carpenter J, Randolph PH, Unverferth DV. Cardiovascular pharmacology of dopexamine in low output congestive heart failure. American Journal of Cardiology 62: 94–99, 1988
Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 56: 468–472, 1977
Magrini F, Foulds R, Roberts N, Macchi G, Mondadori C, et al. Renal hemodynamic effects of dopexamine hydrochloride. American Journal of Cardiology 62: 53C-56C, 1988
Manners CN, Payling DW, Smith DA. Distribution coefficient, a convenient term for the relation of predictable physicochemical properties to metabolic processes. Xenobiotica 18: 331–350, 1988
Mitchell PD, Smith GW, Wells E, West PA. Inhibition of uptake1 by dopexamine hydrochloride in vitro. British Journal of Pharmacology 92: 265–270, 1987
Mousdale S, Clyburn PA, Mackie AM, Groves ND, Rosen M. Comparison of the effects of dopamine, dobutamine and dopexamine upon renal blood flow: a study in normal healthy volunteers. British Journal of Clinical Pharmacology 25: 555–560, 1988
Murphy JJ, Hampton JR. Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure. British Heart Journal 60: 45–49, 1988
Neale MG, Baker P, Brown K, Foulds RA, Morris DA. Pharmacokinetics and metabolism of dopexamine in man. Abstract. Acta Pharmacologica et Toxicologica 59: 69, 1986
Nedergaard OA. Dopexamine hydrochloride is an inhibitor of the uptake-1 mechanism in rabbit aorta. British Journal of Pharmacology 96: 192P, 1989
Park GR, Bodenham A, Hoskins R. The haematological effects of inotropic agents. 9th World Congress on Intensive and Critical Care Medicine, Kyoto, Japan, May, 1989
Parratt JR, Wainwright CL, Fagbemi O. Effect of dopexamine hydrochloride in the early stages of experimental myocardial infarction and comparison with dopamine and dobutamine. American Journal of Cardiology 62: 18C-23C, 1988
Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Steves Ring W, et al. Heterogeneous myocardial catecholamine concentrations in patients with congestive heart failure. American Journal of Cardiology 60: 316–321, 1987
Richard C, Ricome JL, Rimailho A, Bottineau G, Auzepy P. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 67: 620–626, 1983
Ruffolo RR, Kopia GA. Importance of receptor regulation in the pathophysiology and therapy of congestive cardiac failure. American Journal of Medicine 80 (Suppl. 2B): 67–72, 1986
Smith GW, Hall JC, Farmer JB, Simpson WT. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and β2-adrenoceptors in the dog. Journal of Pharmacy and Pharmacology 39: 636–641, 1987
Smith GW, Naya I. Inhibition of uptake I in the dog by dopexamine hydrochloride. British Journal of Pharmacology 92 (Suppl.): 777P, 1987
Smith GW, O’Connor SE. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride). American Journal of Cardiology 62: 9C-17C, 1988
Svenson G, Strandberg L-E, Lindvall B, Erhardt L. Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion. British Heart Journal 60: 489–496, 1988
Svensson G, Sjögren A, Erhardt L. Short-term haemodynamic effects of dopexamine in patients with chronic congestive heart failure. European Heart Journal 7: 697–703, 1986
Tan L-B, Littler WA, Murray RG. Beneficial haemodynamic effects of intravenous dopexamine in patients with low-output heart failure. Journal of Cardiovascular Pharmacology 10: 280–286, 1987a
Tan LB, Murray RG, Littler WA. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe heart failure. Abstract. British Heart Journal 61: 87–88, 1989
Tan LB, Smith SA, Littler WA, Murray RG. Haemodynamic and renal effects of dopexamine in low-output heart failure. Abstract. British Heart Journal 57: 81, 1987b
Unverferth DV, Blanford M, Kates RE, Leier CV. Tolerance to dobutamine after a 72 hour continuous infusion. American Journal of Medicine 69: 262–266, 1980
Van der Starre PJA, Rosseel PMJ. Dopexamine hydrochloride after coronary artery bypass grafting. American Journal of Cardiology 62: 78C-82C, 1988
Vatner DE, Vatner SF, Fujii AM, Homey CJ. Loss of high affinity cardiac beta-adrenergic receptors in dogs with heart failure. Journal of Clinical Investigation 76: 2259–2264, 1985
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: G.P. Biro, Department of Physiology, University of Ottawa, Ottawa, Canada; R.E.S. Bullingham, Banbury, England; D.C. Harrison, University of Cincinnati Medical Center, Cincinnati, Ohio, USA; A.O. Molajo, Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland; L.M. Opie, Department of Medicine, University of Cape Town, Cape Town, South Africa; D.N. Sharpe, Department of Medicine, Auckland Hospital, Auckland, New Zealand.
Rights and permissions
About this article
Cite this article
Fitton, A., Benfield, P. Dopexamine Hydrochloride. Drugs 39, 308–330 (1990). https://doi.org/10.2165/00003495-199039020-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199039020-00009